[{"address1": "9804 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 552 8181", "website": "https://www.regenxbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 344, "companyOfficers": [{"maxAge": 1, "name": "Mr. Curran M. Simpson M.S.", "age": 61, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 698604, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vittal K. Vasista", "age": 55, "title": "Executive VP & CFO", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 666498, "exercisedValue": 573300, "unexercisedValue": 352981}, {"maxAge": 1, "name": "Dr. Olivier  Danos Ph.D.", "age": 65, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 778851, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pakola M.D.", "age": 54, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 674050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick J. Christmas II, J.D.", "age": 52, "title": "Executive VP & Chief Legal Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1111209, "exercisedValue": 1294231, "unexercisedValue": 140919}, {"maxAge": 1, "name": "Ms. Shiva G. Fritsch", "title": "Chief Communications & People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ram  Palanki Pharm.D.", "age": 47, "title": "Executive VP of Commercial Strategy & Operations", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.28, "open": 11.24, "dayLow": 11.08, "dayHigh": 11.47, "regularMarketPreviousClose": 11.28, "regularMarketOpen": 11.24, "regularMarketDayLow": 11.08, "regularMarketDayHigh": 11.47, "beta": 1.218, "forwardPE": -6.54023, "volume": 598017, "regularMarketVolume": 598017, "averageVolume": 574288, "averageVolume10days": 369440, "averageDailyVolume10Day": 369440, "bid": 11.35, "ask": 11.41, "bidSize": 200, "askSize": 200, "marketCap": 562436032, "fiftyTwoWeekLow": 10.49, "fiftyTwoWeekHigh": 28.8, "priceToSalesTrailing12Months": 6.3163834, "fiftyDayAverage": 12.3096, "twoHundredDayAverage": 16.0756, "currency": "USD", "enterpriseValue": 425851552, "profitMargins": -2.70738, "floatShares": 40801807, "sharesOutstanding": 49423200, "sharesShort": 5728866, "sharesShortPriorMonth": 4810250, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1159, "heldPercentInsiders": 0.072919995, "heldPercentInstitutions": 0.9247, "shortRatio": 11.18, "shortPercentOfFloat": 0.1517, "bookValue": 7.062, "priceToBook": 1.6114416, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -241076000, "trailingEps": -5.24, "forwardEps": -1.74, "pegRatio": -0.19, "enterpriseToRevenue": 4.782, "enterpriseToEbitda": -1.884, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RGNX", "underlyingSymbol": "RGNX", "shortName": "REGENXBIO Inc.", "longName": "REGENXBIO Inc.", "firstTradeDateEpochUtc": 1442496600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9b6dd483-8fa5-3249-9e04-c997936abce9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.38, "targetHighPrice": 52.0, "targetLowPrice": 21.0, "targetMeanPrice": 38.08, "targetMedianPrice": 39.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 290356992, "totalCashPerShare": 5.875, "ebitda": -226024000, "totalDebt": 158715008, "quickRatio": 3.414, "currentRatio": 3.528, "totalRevenue": 89044000, "debtToEquity": 45.573, "revenuePerShare": 1.933, "returnOnAssets": -0.24261, "returnOnEquity": -0.63936, "freeCashflow": -105627872, "operatingCashflow": -191119008, "revenueGrowth": 0.116, "grossMargins": -1.98511, "ebitdaMargins": -2.53834, "operatingMargins": -2.51343, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]